Adaptive Biotechnologies Corporation Common Stock (ADPT)
Stock · NASDAQ · Health Care
$24.03as of 10/16/2026
Price chart
Active signals
ADPT Signal Track Record
How signals performed across all stocks →What ADPT's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 36 | +1.9% | 50% | October 1, 2026 |
| Bollinger Band Breakout | 27 | -0.1% | 48% | September 16, 2026 |
| Bollinger Band BreakdownActive now | 19 | +1.6% | 58% | May 13, 2026 |
| 200-Day Moving Average TouchActive now | 7 | -5.8% | 29% | May 28, 2026 |
| Any 20-session window (baseline) | +3.4% | 57% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ADPT
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 624
- Website
- www.adaptivebiotech.com
Fundamentals
- 1-day range
- $23.95$25.51
- Market cap
- $3.77B
- P/E (trailing)
- —
- P/E (forward)
- -133.23
- EPS (trailing)
- $-0.41
- Dividend yield
- —
- Beta
- 2.16
- Avg. volume
- 2.33M
How Adaptive Biotechnologies Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 26, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Adaptive Biotechnologies Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- ADPTAdaptive Biotechnologies Corporation Common Stock$24.02▼ 6.10%Market cap $3.77BP/E —$12$30.74
- RLAYRelay Therapeutics Inc. Common Stock$16.28▼ 5.90%Market cap $3.78BP/E —$5.95$21.27
- DNLIDenali Therapeutics Inc. Common Stock$17.61▼ 3.98%Market cap $3.92BP/E —$13.75$27.3
- KODKodiak Sciences Inc Common Stock$85.75▼ 2.69%Market cap $2.84BP/E —$10.94$104
- BEAMBeam Therapeutics Inc. Common Stock$23.47▼ 5.10%Market cap $2.81BP/E —$20.23$38.26
- TARSTarsus Pharmaceuticals Inc. Common Stock$68.07▼ 4.11%Market cap $2.81BP/E —$53.89$91.53
- IOVAIovance Biotherapeutics Inc. Common Stock$13.62▼ 7.47%Market cap $2.77BP/E —$1.76$15.3
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ADPT Adaptive Biotechnologies Corporation Common Stock | $3.77B | — | $24.02 | ▼ 6.10% | $12$30.74 |
| RLAY Relay Therapeutics Inc. Common Stock | $3.78B | — | $16.28 | ▼ 5.90% | $5.95$21.27 |
| DNLI Denali Therapeutics Inc. Common Stock | $3.92B | — | $17.61 | ▼ 3.98% | $13.75$27.3 |
| KOD Kodiak Sciences Inc Common Stock | $2.84B | — | $85.75 | ▼ 2.69% | $10.94$104 |
| BEAM Beam Therapeutics Inc. Common Stock | $2.81B | — | $23.47 | ▼ 5.10% | $20.23$38.26 |
| TARS Tarsus Pharmaceuticals Inc. Common Stock | $2.81B | — | $68.07 | ▼ 4.11% | $53.89$91.53 |
| IOVA Iovance Biotherapeutics Inc. Common Stock | $2.77B | — | $13.62 | ▼ 7.47% | $1.76$15.3 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32benzinga · 10/13/2026
- Could You Have Seen The Run In Tempus AI Stock Coming?Yahoo · 10/9/2026
- Adaptive Biotechnologies (ADPT) Stock Sees Modest Fair Value Lift On MRD OptimismYahoo · 10/8/2026
- Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $32Benzinga · 10/1/2026
- Goldman Sachs Initiates Coverage On Adaptive Biotechnologies with Buy Rating, Announces Price Target of $35Benzinga · 9/29/2026
- Adaptive Biotechnologies (ADPT) Stock Could Be 26% Above Fair Value Despite Guideline UpdateYahoo · 9/25/2026
- Adaptive Biotechnologies Highlights Role of Highly Sensitive MRD Testing in New International Myeloma Society Definition of CureYahoo · 9/25/2026
- Adaptive Biotechnologies (ADPT) Jumped, So What Is Driving Attention Now?Yahoo · 9/25/2026
- NCCN’s Myeloma MRD Update Spotlighting clonoSEQ Could Be A Game Changer For Adaptive Biotechnologies (ADPT)Yahoo · 9/24/2026
Insider Activity
Insider Actions →- Julie Rubinstein · October 8, 2026 · Option Exercise11.9K @ $12.14
- Julie Rubinstein · October 8, 2026 · Sale11.9K @ $25.66
- Julie Rubinstein · October 7, 2026 · Option Exercise11.9K @ $12.14
- Julie Rubinstein · October 7, 2026 · Sale11.9K @ $26.4
- Susan Bobulsky · October 6, 2026 · Sale6.4K @ $30
- Julie Rubinstein · October 6, 2026 · Option Exercise11.9K @ $12.14
- Julie Rubinstein · October 6, 2026 · Sale499 @ $30.53
- Julie Rubinstein · October 6, 2026 · Sale901 @ $29.71
- Julie Rubinstein · October 6, 2026 · Sale1.1K @ $28.21
- Julie Rubinstein · October 6, 2026 · Sale9.4K @ $27.36
- Julie Rubinstein · October 5, 2026 · Option Exercise11.9K @ $12.14
- Julie Rubinstein · October 5, 2026 · Sale5.2K @ $29.67
- Julie Rubinstein · October 5, 2026 · Sale6.7K @ $28.82
- Julie Rubinstein · October 2, 2026 · Option Exercise11.9K @ $12.14
- Julie Rubinstein · October 2, 2026 · Sale11.9K @ $28.13
Institutional Ownership
March 31, 2026
- Total shares held
- 145.26M
- Total value held
- $1.92B
- Institutional holders
- 287
- Unknown29.99M
- Unknown13.30M
- Unknown6.09M
- Unknown5.44M
- Unknown4.45M
- Unknown3.86M
- Unknown3.64M
- Unknown3.54M
- Unknown3.24M
- Unknown3.23M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism
Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.
Adaptive Biotechnologies Fair Value Lifted on MRD Optimism. Adaptive Biotechnologies saw a modest increase in its fair value estimate driven by optimism regarding minimal residual disease (MRD) data. This development provides a fundamental reason for potential valuation adjustments, distinct from the technical indicators currently showing a negative divergence. The stock remains within its 52-week range, with analysts maintaining a higher average target price than the current market levels.